ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011

Also written as “T3011”, “T3011 high dose” and “T3011 middle dose”.

Its studies are mostly in Melanoma · Urinary Bladder Neoplasms · Carcinoma, Hepatocellular · Sarcoma · Lung Neoplasms, led by 2 companies.

Drug pageOncolytic HSV-1 Expressing IL-12 and Anti-PD-1 Antibody T3011: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 14, 20208 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ImmVira Pharmaits history only63 open or runningphase 2since Apr 14, 2020Apr 14, 2020Dec 31, 2028phase 2 · NCT06971614
Shanghai Pharmaceuticalsits history only22 open or runningphase 2since Jan 9, 2024Jan 9, 2024Dec 31, 2026phase 2 · NCT06214143

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2020First study: phase 2 study in MelanomaNew to ImmVira PharmaImmVira Pharma · NCT04370587 · 30 planned · United States, Australia
  2. Feb 6, 2021Phase 2 study in Carcinoma, HepatocellularImmVira Pharma · NCT04780217 · 42 enrolled · United States
  3. Oct 18, 20222 phase 2 studiesImmVira Pharma · NCT05602792, NCT05598268
  4. Dec 23, 2022Phase 2 study in MelanomaImmVira Pharma · NCT05756556 · 68 enrolled · United States
  5. Jan 9, 2024Shanghai Pharmaceuticals’ first studies: 2 phase 2 studiesNew to Shanghai PharmaceuticalsShanghai Pharmaceuticals · NCT06214156, NCT06214143
  6. Apr 27, 2025Phase 2 study in Nonmuscle-invasive Bladder CancerImmVira Pharma · NCT06971614 · 160 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Advanced Solid TumorsShanghai Pharmaceuticals · NCT06214143
  2. Dec 31, 2028Primary completion: phase 2 study in Nonmuscle-invasive Bladder CancerImmVira Pharma · NCT06971614

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06971614Nonmuscle-invasive Bladder Cancer · United States2RecruitingImmVira PharmaDec 31, 2028160
NCT06214156Advanced Melanoma · China2RecruitingShanghai PharmaceuticalsSep 30, 202642
NCT06214143Advanced Solid Tumors · China2RecruitingShanghai PharmaceuticalsDec 31, 202668
NCT05756556Melanoma · United States2SuspendedImmVira PharmaDec 31, 202668
NCT05602792Sarcoma · China2UNKNOWNImmVira PharmaJul 2023233
NCT05598268Lung Neoplasms · China2UNKNOWNImmVira PharmaJun 202474
NCT04780217Carcinoma, Hepatocellular · United States2Active, not recruitingImmVira PharmaMar 202542
NCT04370587Melanoma · United States, Australia2RecruitingImmVira PharmaSep 22, 202630

How it is read

Names in the registry

  • “T3011”, 12 entries
  • “T3011 high dose”, 1 entry
  • “T3011 middle dose”, 1 entry
  • “T3011 low dose”, 1 entry
  • “T3011 + pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.